JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
JP Morgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Overweight rating and announces Price Target of $9.
JP Morgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Overweight rating and announces Price Target of $9.